Author

E. Voest

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Research Focus:variant effect prediction· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:CRISPR screen· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:genome assembly· 1 Research Focus:variant calling· 1

Frequent Co-Authors

A. Jurgens· 1 shared A. Martinez-Marti· 1 shared A. R. Bassett· 1 shared A. van Hoeck· 1 shared A. Villanueva· 1 shared C. Dincer· 1 shared C. Hardy· 1 shared C. M. Cattaneo· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Jurgens

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Base editing screens map mutations affecting IFNγ signalling in cancer

M. A. Coelho, E. Karakoc, S. G. Bhosle, E. Goncalves, T. Burgold, S. Cooper, C. M. Cattaneo, V. Veninga, S. Consonni, C. Dincer, S. F. Vieira, F. Gibson, S. Barthorpe, C. Hardy, J. Rein, , M. J. Garnett

This study uses base editing to identify mutations affecting IFNγ signalling in cancer, revealing loss- and gain-of-function variants with clinical relevance.

bioRxiv · Mar 29, 2022 · PreprintCancer Biology

Multiple Low Dose therapy: an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

J. M. Fernandes Neto, E. Nadal, S. N. Ooft, E. Bosdriesz, L. Farre, C. McLean, S. Klarenbeek, A. Jurgens, H. Hagen, L. Wang, E. Felip, A. Martinez-Marti, E. Voest, L. Wessels, O. van Tellingen, , R. Bernards

This paper shows that using multiple low doses of drugs targeting different components of a signaling pathway can effectively treat EGFR inhibitor-resistant NSCLC without resistance development.

bioRxiv · Oct 29, 2019Cancer Biology

Pan-cancer whole genome analyses of metastatic solid tumors

P. Priestley, J. Baber, M. Lolkema, N. Steeghs, E. de Bruijn, K. Duyvesteyn, S. Haidari, A. van Hoeck, W. Onstenk, P. Roepman, C. Shale, M. Voda, H. Bloemendal, V. Tjan-Heijnen, C. van Herpen, , E. Cuppen

This study analyzes whole genome sequences of metastatic solid tumors to identify genetic variants that may influence treatment outcomes.

bioRxiv · Aug 12, 2019 · PreprintCancer Biology